Thomas Buroker, DO
Medical Oncology · Ankeny, IANPI 1982665337
Payments from drug & device makers
What this record shows
This record is dominated by education: $23 of the $23 with a category attached, or 100.0%. That places this record below the midpoint for medical oncology clinicians in IA, where the typical reported total is $879.
Across 2 payments — averaging $11.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12
- Epizyme, Inc.$12
What the payments were for
- Education$23100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$23 in reported general payments places this provider in the 5th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 88 | $1,243,764 |
| LynparzaOlaparib | 50 | $802,751 |
| CalquenceAcalabrutinib Maleate | 72 | $790,800 |
| LeukeranChlorambucil | 27 | $434,355 |
| RevlimidLenalidomide | 18 | $379,044 |
| IbrancePalbociclib | 22 | $340,738 |
| Lenalidomide | 22 | $286,846 |
| AlecensaAlectinib Hcl | 13 | $245,822 |
| GavretoPralsetinib | 11 | $216,838 |
| ImbruvicaIbrutinib | 12 | $178,926 |
| InlytaAxitinib | 12 | $132,670 |
| BrukinsaZanubrutinib | 12 | $100,683 |
| Abiraterone Acetate | 20 | $45,123 |
| EliquisApixaban | 34 | $18,099 |
| XareltoRivaroxaban | 17 | $13,531 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ankeny
- Zeeshan JawaAnkeny$4K
- Mark WestbergAnkeny$1K
- Joshua LukenbillAnkeny$682
- Robert ShreckAnkeny$125
- Daniel BurokerAnkeny$49
- Tara GraffClive$702K
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.